EGFR-targeted therapy plus immunotherapy for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining two types of cancer drugs—a targeted pill that attacks a specific mutation in your lung cancer cells, followed by an immunotherapy injection when your tumor stops shrinking. The goal is to see if this combination works better than standard treatment alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Advanced or metastatic non-small cell lung cancer (NSCLC) with an EGFR mutation (specifically 19del or L858R)
- Never received immunotherapy (PD-1 or PD-L1 drugs) before
- Age 18 or older with good overall health and physical function
- No severe lung, heart, liver, or kidney disease, and no active infections
- Not taking immunosuppressive drugs or steroids in the past 2 weeks
- Willing to use effective birth control if you can have children
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different treatment plans before lung cancer surgery. Both plans start with a targeted pill (limertinib), then one adds immunotherapy plus chemotherapy, and the other adds just chemotherapy. The goal is to see which combination helps shrink the tumor more before surgery.
This trial tests a new treatment for advanced non-small cell lung cancer that has stopped responding to a targeted pill (EGFR-TKI). It combines your own immune cells, grown in a lab, with another targeted pill to try to fight the cancer.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy can help people with advanced non-small cell lung cancer that carries an EGFR exon 21 mutation and shows PD-L1 expression. The goal is to see if this combination helps shrink tumors or slow cancer growth more effectively.
This trial tests whether adding radiation therapy to a drug combination can help people with a specific type of lung cancer that has stopped responding to standard first-line pills. It's for patients whose cancer has a certain gene change (EGFR) and has spread to other parts of the body.
This trial tests whether taking an EGFR-targeted pill after lung cancer surgery can lower the chance of the cancer coming back. It is for people with early-stage non-small cell lung cancer that has a specific EGFR mutation.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
Hear when a new Lung Cancer Non-Small Cell Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.